BlueCross BlueShield of Tennessee Medical Policy Manual

Analysis of Proteomic Patterns in Serum for Early Detection of Cancer

DESCRIPTION

Proteomic patterns are patterns of proteins present within a clinical sample (serum, urine, tissue) used as a diagnostic ‘fingerprint’ that is proposed to provide an early diagnosis for some types of cancer. The proteomic pattern does not rely on the identification of any single protein or biomarker. For pattern recognition, one technology used is called surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), which is a type of mass spectrometry, that measures the relative quantity of different proteins in a particular sample.

POLICY

See also:  

IMPORTANT REMINDERS

ADDITIONAL INFORMATION

Published scientific evidence in the form of well-designed studies in peer-reviewed journals regarding the analysis of proteomic patterns in serum to identify ovarian, prostate or other types of cancer continues to be lacking. There is insufficient evidence to permit conclusions regarding the use of this technology.

SOURCES

Conrads, T., Zhou, M., Petricoin, E., Liotta, L., and Veenstra, T. (2003) Cancer diagnosis using proteomic patterns. Expert Review in Molecular Diagnostics, 3(4), 411-421. (Level 5 evidence)

Lim, L., Looi, M., Zakaria, S., Sagap, I., Rose, I., Chin, S., et al. (2016). Identification of differentially expressed proteins in the serum of colorectal cancer patients using 2D-DIGE proteomics analysis. Pathology Oncology Research, 22, 169-177. (Level 4 evidence)

National Cancer Institute / Clinical Proteomic Tumor Analysis Consortium. (2011, December). Interrogating cancer biology to address clinically relevant questions (fact sheet). Retrieved January 18, 2011 from http://www.cancer.gov.

Shao, S., Neely, B. A., Kao, T. C., Eckhaus, J., Bourgeois, J., Brooks, J., et al. (2016). Proteomic profiling of serial pre-diagnostic serum samples for early detection of colon cancer in the U. S. military. Cancer Epidemiology Biomarkers Prevention, 2016, Epub ahead of print. Abstract retrieved February 2, 2017 from PubMed database.

Tanase, C., Albulescu, R., Codrici, E., Popescu, D., Mihai, S., Enciu, A., et al. (2015) Circulating biomarker panels for targeted therapy in brain tumors. Future Oncology, 11(3), 511-524. (Level 5 evidence)

Tinelli, A., Vergara, D., Martignago, R., Leo, G., Pisano, M. & Malvasi, A. (2009). An outlook on ovarian cancer and borderline ovarian tumors: Focus on genomic and proteomics findings. Current Genomics, 10 (4), 240-249.

Xu, Y., Zhuo, J., Duan, Y., Shi, B., Chen, X. Zhang, X., et al., (2014, July). Construction of protein profile classification model and screening of proteomic signature of acute leukemia. International Journal of Clinical Expert Pathology 2014; 7 (9), 5569-5581. (Level 4 evidence - Independent)

ORIGINAL EFFECTIVE DATE:  8/13/2005

MOST RECENT REVIEW DATE:  1/25/2018

ID_BT

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.